An Italian consensus for invasive candidiasis management (ITALIC)

Infection

Volumn 42, Issue 2, 2014, Pages 263-279

  Scudeller, L ^a   Viscoli, C ^b   Menichetti, F ^c   Del Bono, V ^b   Cristini, F ^d   Tascini, C ^c   Bassetti, M ^e   Viale, P ^d  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c CISANELLO HOSPITAL   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Clinical severity; Consensus; Diagnosis; Invasive candidiasis; Management; Recommendations; Review; Risk stratification

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; DEOXYCHOLIC ACID; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MANNAN; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ANTIMICROBIAL THERAPY; BLOOD CULTURE; BONE AND JOINT INFECTIONS; CANDIDA ENDOCARDITIS; CANDIDURIA; CENTRAL NERVOUS SYSTEM INFECTION; CONSENSUS DEVELOPMENT; ECHOCARDIOGRAPHY; EYE EXAMINATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; INVASIVE CANDIDIASIS; MEDICAL SOCIETY; NONHUMAN; PRACTICE GUIDELINE; REVIEW; TREATMENT DURATION; CANDIDIASIS, INVASIVE; CONSENSUS; EPIDEMIOLOGY; ITALY; RISK FACTOR;

ANTIFUNGAL AGENTS; CANDIDIASIS, INVASIVE; CONSENSUS; HUMANS; ITALY; RISK FACTORS;

EID: 84897528421     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-013-0558-0     Document Type: Review

References (166)

1. Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012;54:1739-46. doi:10.1093/cid/cis305.
2. Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One. 2011;6:e24198. doi:10.1371/journal.pone.0024198.
3. Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis RJ, Messer SA. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. J Clin Microbiol. 1998;36:1886-9. (Pubitemid 28277770)
4. Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis. 1997;24:584-602. (Pubitemid 27143552)
5. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999;29:239-44. doi:10.1086/520192. (Pubitemid 29380177)
6. Nguyen MH, Peacock JE Jr, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med. 1996;100:617-23 (pii:S0002934395000100).
7. Rocco TR, Reinert SE, Simms HH. Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance. Arch Surg. 2000;135:160-5. (Pubitemid 30078468)
8. Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis. 2006;6:21. doi:10.1186/1471-2334-6-21.
9. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640-5. doi:10.1128/AAC.49.9.3640-3645.2005. (Pubitemid 41233011)
10. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25-31. doi:10.1086/504810. (Pubitemid 43939072)
11. Hsu DI, Nguyen M, Nguyen L, Law A, Wong-Beringer A. A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. J Antimicrob Chemother. 2010;65:1765-70. doi:10.1093/jac/dkq216.
12. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-35. doi:10.1086/596757.
13. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2013;18:19-37. doi:10.1111/1469-0691.12039.
14. Clancy CJ, Nguyen MH. Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56:1284-1292. doi:10.1093/cid/cit006.
15. Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS One. 2011;6:e20476. doi:10.1371/journal.pone.0020476.
16. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-6. doi:10.1136/bmj.39489.470347.AD. (Pubitemid 351632017)
17. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is "quality of evidence" and why is it important to clinicians? BMJ. 2008;336:995-8. doi:10.1136/bmj.39490.551019.BE. (Pubitemid 351656090)
18. Jaeschke R, Guyatt GH, Dellinger P, Schünemann H, Levy MM, Kunz R, et al. Use of GRADE grid to reach decisions on clinical practice guidelineswhen consensus is elusive. BMJ. 2008;337:a744.
19. Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336:1106-10. doi:10.1136/bmj.39500. 677199.AE. (Pubitemid 351731739)
20. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. Going from evidence to recommendations. BMJ. 2008;336:1049-51. doi:10.1136/bmj.39493.646875.AE.
21. National Institute for Health and Clinical Excellence (NICE). The guidelines manual. Last updated January 2009.
22. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother. 2011;55:532-8. doi:10.1128/AAC.01128-10.
23. Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, Grenouillet F, Cassaing S, Baixench MT, et al. Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg Infect Dis. 2012;18:86-90. doi:10.3201/eid1801.110556.
24. Viale P. Candida colonization and candiduria in critically ill patients in the intensive care unit. Drugs. 2009;69:51-7. doi:10.2165/11315640-000000000- 00000.
25. Ben-Ami R, Weinberger M, Orni-Wasserlauff R, Schwartz D, Itzhaki A, Lazarovitch T, et al. Time to blood culture positivity as a marker for catheter-related candidemia. J Clin Microbiol. 2008;46:2222-6. doi:10.1128/JCM.00214-08.
26. American College of Chest Physicians/Society of Critical Care. Medicine consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-74.
27. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220:751-8. (Pubitemid 24376373)
28. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol. 2005;43:235-43. (Pubitemid 40867497)
29. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis. 2007;26:271-6. doi:10.1007/s10096-007- 0270-z. (Pubitemid 46572022)
30. León C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, et al. A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006;34:730-7. doi:10.1097/01.CCM. 0000202208.37364.7D.
31. León C, Ruiz-Santana S, Saavedra P, Galván B, Blanco A, Castro C, et al. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med. 2009;37:1624-33. doi:10.1097/CCM.0b013e31819daa14.
32. Eggimann P, Ostrosky-Zeichner L. Early antifungal intervention strategies in ICU patients. Curr Opin Crit Care. 2010;16:465-9. doi:10.1097/MCC. 0b013e32833e0487.
33. Posteraro B, De Pascale G, Tumbarello M, Torelli R, Pennisi MA, Bello G, et al. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1 → 3)-beta-D-glucan assay, Candida score, and colonization index. Crit Care. 2011;15:R249. doi:10.1186/cc10507.
34. Ostrosky-Zeichner L, Pappas PG, Shoham S, Reboli A, Barron MA, Sims C, et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses. 2009;54:46-51. doi:10.1111/j.1439-0507.2009.01756.x.
35. Playford EG, Lipman J, Sorrell TC. Prophylaxis, empirical and preemptive treatment of invasive candidiasis. Curr Opin Crit Care. 2010;16:470-4. doi:10.1097/MCC.0b013e32833e10e8.
36. Hermsen ED, Zapapas MK, Maiefski M, Rupp ME, Freifeld AG, Kalil AC. Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: a matched case-control study. Crit Care. 2011;15:R198. doi:10.1186/cc10366.
37. Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med. 2009;37:1612-8. doi:10.1097/CCM. 0b013e31819efac0.
38. Charles PE, Castro C, Ruiz-Santana S, León C, Saavedra P, Martín E. Serum procalcitonin levels in critically ill patients colonized with Candida spp.: new clues for the early recognition of invasive candidiasis? Intensive Care Med. 2009;35:2146-50. doi:10.1007/s00134-009-1623-0.
39. Berenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis. 1993;17:103-9 (pii:0732-8893(93)90020-8).
40. Ellis M, Al-Ramadi B, Bernsen R, Kristensen J, Alizadeh H, Hedstrom U. Prospective evaluation of mannan and anti-mannan antibodies for diagnosis of invasive Candida infections in patients with neutropenic fever. J Med Microbiol. 2009;58:606-15. doi:10.1099/jmm.0.006452-0.
41. Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care. 2010;14:R222. doi:10.1186/cc9365.
42. Tokunaga S, Ohkawa M, Takashima M. Diagnostic value of determination of serum mannan concentrations in patients with candiduria. Eur J Clin Microbiol Infect Dis. 1993;12:542-5. (Pubitemid 23241805)
43. Verduyn Lunel FM, Donnelly JP, van der Lee HA, Blijlevens NM, Verweij PE. Circulating Candida-specific anti-mannan antibodies precede invasive candidiasis in patients undergoing myelo-ablative chemotherapy. Clin Microbiol Infect. 2009;15:380-6. doi:10.1111/j.1469-0691.2008.02654.x.
44. Arendrup MC, Bergmann OJ, Larsson L, Nielsen HV, Jarløv JO, Christensson B. Detection of candidaemia in patients with and without underlying haematological disease. Clin Microbiol Infect. 2009;16:855-62. doi:10.1111/j.1469-0691.2009.02931.x.
45. Hsu JL, Ruoss SJ, Bower ND, Lin M, Holodniy M, Stevens DA. Diagnosing invasive fungal disease in critically ill patients. Crit Rev Microbiol. 2011;37:277-312. doi:10.3109/1040841X.2011.581223.
46. Laín A, Elguezabal N, Moragues MD, García-Ruiz JC, del Palacio A, Pontón J. Contribution of serum biomarkers to the diagnosis of invasive candidiasis. Expert Rev Mol Diagn. 2008;8:315-25. doi:10.1586/ 14737159.8.3.315. (Pubitemid 351724710)
47. Preuner S, Lion T. Towards molecular diagnostics of invasive fungal infections. Expert Rev Mol Diagn. 2009;9:397-401. doi:10.1586/erm.09.27.
48. Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1 → 3)-beta-D-glucan assay for the diagnosis of invasive fungal infections - a study based on autopsy cases from 6 years. Clin Infect Dis. 2008;46:1864-70. doi:10.1086/588295.
49. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004;39:199-205. doi:10.1086/421944. (Pubitemid 38971490)
50. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, et al. Multicenter clinical evaluation of the (1 → 3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005;41:654-9. doi:10.1086/432470. (Pubitemid 41170353)
51. Perlin DS. Antifungal drug resistance: do molecular methods provide a way forward? Curr Opin Infect Dis. 2009;22:568-73. doi:10.1097/QCO. 0b013e3283321ce5.
52. Kourkoumpetis TK, Fuchs BB, Coleman JJ, Desalermos A, Mylonakis E. Polymerase chain reaction-based assays for the diagnosis of invasive fungal infections. Clin Infect Dis. 2012;54:1322-31. doi:10.1093/cid/cis132.
53. Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol. 2011;49:665-70. doi:10.1128/JCM.01602-10.
54. Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE, et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med. 2009;35:1526-31. doi:10.1007/s00134-009-1482-8.
55. Gadea I, Cuenca-Estrella M, Martín E, Pemán J, Pontón J, Rodríguez-Tudela JL. Microbiological procedures for diagnosing mycoses and for antifungal susceptibility testing. Enferm Infecc Microbiol Clin. 2007;25:336-40; 13102270 [pii].
56. Richardson M, Ellis M. Clinical and laboratory diagnosis. Hosp Med. 2000;61:610-4.
57. Ruhnke M, Rickerts V, Cornely OA, Buchheidt D, Glöckner A, Heinz W, et al. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses. 2011;54:279-310. doi:10.1111/j.1439-0507.2011.02040.x.
58. Clinical and Laboratory Standards Institute (CLSI). Principles and procedures for blood cultures; Approved guideline. CLSI document M47-A. Wayne, PA: CLSI; 2007.
59. Lee A, Mirrett S, Reller LB, Weinstein MP. Detection of bloodstream infections in adults: how many blood cultures are needed? J Clin Microbiol. 2007;45:3546-8. doi:10.1128/JCM.01555-07. (Pubitemid 350156846)
60. Washington JA 2nd. Blood cultures: principles and techniques. Mayo Clin Proc. 1975;50:91-8.
61. Cockerill FR 3rd, Wilson JW, Vetter EA, Goodman KM, Torgerson CA, Harmsen WS, et al. Optimal testing parameters for blood cultures. Clin Infect Dis. 2004;38:1724-30. doi:10.1086/421087. (Pubitemid 38781664)
62. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:1-45. doi:10.1086/599376.
63. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. Beta-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011;52:750-70. doi:10.1093/cid/ciq206.
64. Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A. Contribution of the (1 → 3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2008;46:1009-13. doi:10.1128/JCM.02091-07. (Pubitemid 351379994)
65. Del Bono V, Delfino E, Furfaro E, Mikulska M, Nicco E, Bruzzi P, et al. Clinical performance of the (1,3)-beta-D-glucan assay in early diagnosis of nosocomial Candida bloodstream infections. Clin Vaccine Immunol. 2011;18:2113-7. doi:10.1128/CVI.05408-11.
66. Eggimann P, Marchetti O. Is (1 → 3)-beta-D-glucan the missing link from bedside assessment to pre-emptive therapy of invasive candidiasis? Crit Care. 2011;15:1017. doi:10.1186/cc10544.
67. Presterl E, Parschalk B, Bauer E, Lassnigg A, Hajdu S, Graninger W. Invasive fungal infections and (1,3)-beta-D-glucan serum concentrations in long-term intensive care patients. Int J Infect Dis. 2009;13:707-12. doi:10.1016/j.ijid.2008.10.013.
68. Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder W, Williams D. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol. 2003;10:882-5. (Pubitemid 37129504)
69. Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL. Evaluation of a (1 → 3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2005;43:5957-62. doi:10.1128/JCM.43.12.5957-5962.2005. (Pubitemid 43100644)
70. Takesue Y, Kakehashi M, Ohge H, Imamura Y, Murakami Y, Sasaki M, et al. Combined assessment of beta-D-glucan and degree of candida colonization before starting empiric therapy for candidiasis in surgical patients. World J Surg. 2004;28:625-30. doi:10.1007/s00268-004-7302-y. (Pubitemid 38802803)
71. Mohr JF, Sims C, Paetznick V, Rodriguez J, Finkelman MA, Rex JH, et al. Prospective survey of (1 → 3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. J Clin Microbiol. 2011;49:58-61. doi:10.1128/JCM.01240-10.
72. Koo S, Bryar JM, Page JH, Baden LR, Marty FM. Diagnostic performance of the (1 → 3)-beta-D-glucan assay for invasive fungal disease. Clin Infect Dis. 2009;49:1650-9. doi:10.1086/647942.
73. Acosta J, Catalan M, Del Palacio-Pérez-Medel A, Montejo JC, De-La-Cruz-Bértolo J, Moragues MD, et al. Prospective study in critically ill non-neutropenic patients: diagnostic potential of (1,3)-beta-D-glucan assay and circulating galactomannan for the diagnosis of invasive fungal disease. Eur J Clin Microbiol Infect Dis. 2011;31:721-31. doi:10.1007/s10096-011-1365-0.
74. Lamoth F, Cruciani M, Mengoli C, Castagnola E, Lortholary O, Richardson M, et al. beta-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012;54:633-43. doi:10.1093/cid/cir897.
75. Nguyen MH, Wissel MC, Shields RK, Salomoni MA, Hao B, Press EG, et al. Performance of Candida real-time polymerase chain reaction, beta-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis. 2012;54:1240-8. doi:10.1093/cid/cis200.
76. Mokaddas E, Khan ZU, Ahmad S, Nampoory MR, Burhamah M. Value of (1-3)-beta-D-glucan, Candida mannan and Candida DNA detection in the diagnosis of candidaemia. Clin Microbiol Infect. 2011;17:1549-53. doi:10.1111/j.1469-0691. 2011.03608.x.
77. Prella M, Bille J, Pugnale M, Duvoisin B, Cavassini M, Calandra T, et al. Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. Diagn Microbiol Infect Dis. 2005;51:95-101. doi:10.1016/j. diagmicrobio.2004.08.015. (Pubitemid 40215418)
78. Sendid B, Poirot JL, Tabouret M, Bonnin A, Caillot D, Camus D, et al. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol. 2002;51:433-42. (Pubitemid 34450601)
79. Nihtinen A, Anttila VJ, Richardson M, Ruutu T, Juvonen E, Meri T, et al. Factors influencing the performance level of Candida mannan antigen testing in allogeneic stem cell transplant recipients not receiving fluconazole prophylaxis. Transpl Infect Dis. 2011;13:266-72. doi:10.1111/j.1399-3062.2010. 00593.x.
80. Maaroufi Y, Heymans C, De Bruyne JM, Duchateau V, Rodriguez-Villalobos H, Aoun M, et al. Rapid detection of Candida albicans in clinical blood samples by using a TaqMan-based PCR assay. J Clin Microbiol. 2003;41:3293-8. (Pubitemid 36842335)
81. Moreira-Oliveira MS, Mikami Y, Miyaji M, Imai T, Schreiber AZ, Moretti ML. Diagnosis of candidemia by polymerase chain reaction and blood culture: prospective study in a high-risk population and identification of variables associated with development of candidemia. Eur J Clin Microbiol Infect Dis. 2005;24:721-6. doi:10.1007/s10096-005-0041-7. (Pubitemid 41752067)
82. Einsele H, Loeffler J. Contribution of new diagnostic approaches to antifungal treatment plans in high-risk haematology patients. Clin Microbiol Infect. 2008;14:37-45. doi:10.1111/j.1469-0691.2008.01980.x. (Pubitemid 351593915)
83. Falcone M, Barzaghi N, Carosi G, Grossi P, Minoli L, Ravasio V, et al. Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore). 2009;88:160-8. doi:10.1097/MD. 0b013e3181a693f8.
84. Shoham S, Shaffer R, Sweet L, Cooke R, Donegan N, Boyce S. Candidemia in patients with ventricular assist devices. Clin Infect Dis. 2007;44:e9-12. doi:10.1086/509640.
85. Pierrotti LC, Baddour LM. Fungal endocarditis, 1995-2000. Chest. 2002;122:302-10. (Pubitemid 34754179)
86. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54:1110-22. doi:10.1093/cid/cis021.
87. Rodríguez-Adrián LJ, King RT, Tamayo-Derat LG, Miller JW, Garcia CA, Rex JH. Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, and etiology. Medicine (Baltimore). 2003;82:187-202. doi:10.1097/01.md.0000076008.64510.f1. (Pubitemid 36578708)
88. Parke DW 2nd, Jones DB, Gentry LO. Endogenous endophthalmitis among patients with candidemia. Ophthalmology. 1982;89:789-96. (Pubitemid 12039446)
89. Oude Lashof AM, Rothova A, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, et al. Ocular manifestations of candidemia. Clin Infect Dis. 2011;53:262-8. doi:10.1093/cid/cir355.
90. Nagao M, Saito T, Doi S, Hotta G, Yamamoto M, Matsumura Y, et al. Clinical characteristics and risk factors of ocular candidiasis. Diagn Microbiol Infect Dis. 2012;73:149-52. doi:10.1016/j.diagmicrobio.2012.03.006.
91. Koo S, Baden LR, Marty FM. Post-diagnostic kinetics of the (1 → 3)-beta-D-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia. Clin Microbiol Infect. 2012;18:E122-7. doi:10.1111/j.1469-0691.2012.03777.x.
92. Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L. (1,3)-beta-D-Glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis. 2012;55:521-6. doi:10.1093/cid/cis456.
93. Pazos C, Moragues MD, Quindós G, Pontón J, del Palacio A. Diagnostic potential of (1,3)-beta-D-glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients. Rev Iberoam Micol. 2006;23:209-15 (pii:200623209).
94. Eggimann P, Francioli P, Bille J, Schneider R, Wu MM, Chapuis G, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med. 1999;27:1066-72. (Pubitemid 29314312)
95. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med. 2002;28:1708-17. doi:10.1007/s00134-002-1540-y. (Pubitemid 35435471)
96. Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med. 2005;33:1928-35; quiz 36 (pii:00003246-200509000-00005).
97. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003;3:685-702 (pii:S1473309903008016).
98. Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis. 2001;32:1191-200. doi:10.1086/319763. (Pubitemid 32427691)
99. McKinnon PS, Goff DA, Kern JW, Devlin JW, Barletta JF, Sierawski SJ, et al. Temporal assessment of Candida risk factors in the surgical intensive care unit. Arch Surg. 2001;136:1401-8; discussion 9 (pii:soa1025).
100. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis. 2001;33:177-86. doi:10.1086/321811. (Pubitemid 32643332)
101. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and metaanalysis of randomized clinical trials. J Antimicrob Chemother. 2006;57:628-38. doi:10.1093/jac/dki491.
102. Pelz RK, Hendrix CW, Swoboda SM, Diener-West M, Merz WG, Hammond J, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg. 2001;233:542-8. (Pubitemid 32234953)
103. Faiz S, Neale B, Rios E, Campos T, Parsley E, Patel B, et al. Risk-based fluconazole prophylaxis of Candida bloodstream infection in a medical intensive care unit. Eur J Clin Microbiol Infect Dis. 2009;28:689-92. doi:10.1007/s10096- 008-0666-4.
104. Vardakas KZ, Samonis G, Michalopoulos A, Soteriades ES, Falagas ME. Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials. Crit Care Med. 2006;34:1216-24. doi:10.1097/01.CCM.0000208357.05675.C3.
105. Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials. 2009;10:37. doi:10.1186/1745-6215-10-37.
106. Schuster MG, Edwards JE Jr, Sobel JD, Darouiche RO, Karchmer AW, Hadley S, et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med. 2008;149:83-90; 149/2/83 [pii].
107. Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother. 2007;60:613-8. doi:10.1093/jac/ dkm212. (Pubitemid 47299877)
108. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009;136:1237-48. doi:10.1378/chest.09-0087.
109. Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo SK. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother. 2010;54:184-90. doi:10.1128/AAC.00945-09.
110. Montravers P, Dupont H, Gauzit R, Veber B, Auboyer C, Blin P, et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med. 2006;34:646-52. doi:10.1097/01.CCM.0000201889.39443.D2.
111. Montravers P, Mira JP, Gangneux JP, Leroy O, Lortholary O. A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect. 2011;17:1061-7. doi:10.1111/j.1469-0691.2010.03360.x.
112. Karthaus M, Rüping MJ, Cornely OA, Steinbach A, Groll AH, Lass-Flörl C, et al. Current issues in the clinical management of invasive candida infections - the AGIHO, DMykG, ÖGMM and PEG web-based survey and expert consensus conference 2009. Mycoses. 2011;54:e546-56. doi:10.1111/j.1439- 0507.2010.01988.x.
113. Shah DN, Yau R, Weston J, Lasco TM, Salazar M, Palmer HR, et al. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011;66:2146-51. doi:10.1093/jac/dkr244.
114. Kourkoumpetis TK, Velmahos GC, Ziakas PD, Tampakakis E, Manolakaki D, Coleman JJ, et al. The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients. Mycopathologia. 2011;171:85-91. doi:10.1007/s11046-010-9369-3.
115. Shah DN, Yau R, Lasco TM, Weston J, Salazar M, Palmer HR, et al. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole- nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother. 2012;56:3239-43. doi:10.1128/AAC.00019-12.
116. Ha YE, Peck KR, Joo EJ, Kim SW, Jung SI, Chang HH, et al. Impact of first-line antifungal agents on the outcomes and costs of candidemia. Antimicrob Agents Chemother. 2012;56:3950-6. doi:10.1128/AAC.06258-11.
117. Ben-Ami R, Olshtain-Pops K, Krieger M, Oren I, Bishara J, Dan M, et al. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother. 2012;56:2518-23. doi:10.1128/AAC.05947-11.
118. Tortorano AM, Prigitano A, Dho G, Grancini A, Passera M. Antifungal susceptibility profiles of Candida isolates from a prospective survey of invasive fungal infections in Italian intensive care units. J Med Microbiol. 2012;61:389-93. doi:10.1099/jmm.0.037895-0.
119. van der Voort PH, Boerma EC, Yska JP. Serum and intraperitoneal levels of amphotericin B and flucytosine during intravenous treatment of critically ill patients with Candida peritonitis. J Antimicrob Chemother. 2007;59:952-6. doi:10.1093/jac/dkm074. (Pubitemid 47073367)
120. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020-9. doi:10.1056/NEJMoa021585. (Pubitemid 35461658)
121. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369:1519-27. doi:10.1016/S0140-6736(07)60605-9. (Pubitemid 46670281)
122. Reboli AC, Shorr AF, Rotstein C, Pappas PG, Kett DH, Schlamm HT, et al. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC Infect Dis. 2011;11:261. doi:10.1186/1471-2334-11-261.
123. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45:883-93. doi:10.1086/520980. (Pubitemid 47580382)
124. Glöckner A. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin: review of the literature. Eur J Med Res. 2011;16:167-79.
125. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356:2472-82. doi:10.1056/NEJMoa066906. (Pubitemid 46919773)
126. Rodriguez D, Park BJ, Almirante B, Cuenca-Estrella M, Planes AM, Mensa J, et al. Impact of early central venous catheter removal on outcome in patients with candidaemia. Clin Microbiol Infect. 2007;13:788-93. doi:10.1111/j.1469- 0691.2007.01758.x. (Pubitemid 47039912)
127. Gafter-Gvili A, Vidal L, Goldberg E, Leibovici L, Paul M. Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc. 2008;83:1011-21. doi:10.4065/83.9.1011.
128. Ruhnke M, Paiva JA, Meersseman W, Pachl J, Grigoras I, Sganga G, et al. Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. Clin Microbiol Infect. 2012;18:680-7. doi:10.1111/j.1469-0691.2012.03784.x.
129. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother. 2010;55:561-6. doi:10.1128/AAC.01079-10.
130. Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J Antimicrob Agents. 2011;38:65-9. doi:10.1016/j.ijantimicag.2011.02.016.
131. Cantón E, Pemán J, Quindós G, Eraso E, Miranda-Zapico I, Álvarez M, et al. Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia. Antimicrob Agents Chemother. 2011;55:5590-6. doi:10.1128/AAC.00466-11.
132. Blanchard E, Lortholary O, Boukris-Sitbon K, Desnos-Ollivier M, Dromer F, Guillemot D. Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France. Antimicrob Agents Chemother. 2011;55:5358-61. doi:10.1128/AAC.00690-11.
133. Spreghini E, Orlando F, Tavanti A, Senesi S, Giannini D, Manso E, et al. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. J Antimicrob Chemother. 2012;67:2195-202. doi:10.1093/jac/dks180.
134. Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ, et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis. 2009;48:1676-84. doi:10.1086/598933.
135. Dupont BF, Lortholary O, Ostrosky-Zeichner L, Stucker F, Yeldandi V. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care. 2009;13:R159. doi:10.1186/cc8117.
136. Mistro S, Maciel Ide M, de Menezes RG, Maia ZP, Schooley RT, Badaró R. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin Infect Dis. 2012;54:1774-7. doi:10.1093/cid/cis290.
137. Ullmann AJ, Sanz MA, Tramarin A, Barnes RA, Wu W, Gerlach BA, et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis. 2006;43:e29-38. doi:10.1086/505969.
138. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int. 2001;60:1452-9. doi:10.1046/j.1523-1755.2001.00948.x. (Pubitemid 32960039)
139. Anaissie EJ, Darouiche RO, Abi-Said D, Uzun O, Mera J, Gentry LO, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis. 1996;23:964-72. (Pubitemid 26367478)
140. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994;331:1325-30. doi:10.1056/ NEJM199411173312001. (Pubitemid 24347001)
141. Phillips P, Shafran S, Garber G, Rotstein C, Smaill F, Fong I, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis. 1997;16:337-45. (Pubitemid 27271820)
142. Oude Lashof AM, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Schlamm HT, et al. Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia. Antimicrob Agents Chemother. 2012;56:3133-7. doi:10.1128/AAC.05841-11.
143. Mikulska M, Novelli A, Aversa F, Cesaro S, de Rosa FG, Girmenia C, et al. Voriconazole in clinical practice. J Chemother. 2012;24:311-27. doi:10.1179/1973947812Y.0000000051.
144. Tuil O, Cohen Y. Itraconazole IV solution in the treatment of candidemia in non-neutropenic patients. Crit Care. 2003;7:P131.
145. Kullberg BJ, Verweij PE, Akova M, Arendrup MC, Bille J, Calandra T, et al. European expert opinion on the management of invasive candidiasis in adults. Clin Microbiol Infect. 2011;17:1-12. doi:10.1111/j.1469-0691.2011.03615.x.
146. Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect. 2008;56:126-9. doi:10.1016/j.jinf.2007.10.014.
147. Lefort A, Chartier L, Sendid B, Wolff M, Mainardi JL, Podglajen I, et al. Diagnosis, management and outcome of Candida endocarditis. Clin Microbiol Infect. 2012;18:E99-109. doi:10.1111/j.1469-0691.2012.03764.x.
148. Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis. 2011;52:648-53. doi:10.1093/cid/ciq204.
149. Hariprasad SM, Mieler WF, Holz ER, Gao H, Kim JE, Chi J, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol. 2004;122:42-7. doi:10.1001/archopht.122.1.42. (Pubitemid 38063603)
150. Kujath P, Lerch K, Kochendörfer P, Boos C. Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patientswith systemicmycoses. Infection. 1993;21:376-82.
151. Shah CP, McKey J, Spirn MJ, Maguire J. Ocular candidiasis: a review. Br J Ophthalmol. 2008;92:466-8. doi:10.1136/bjo.2007.133405. (Pubitemid 351497969)
152. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005;366:1435-42. doi:10.1016/S0140-6736(05)67490-9. (Pubitemid 41483809)
153. Ozdemir H, Karbuz A, Ciftçi E, Dinçaslan HU, Ince E, Aysev D, et al. Successful treatment of central venous catheter infection due to Candida lipolytica by caspofungin-lock therapy. Mycoses. 2011;54:e647-9. doi:10.1111/j.1439-0507.2010.01964.x.
154. Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood. 2005;106:2641-5. doi:10.1182/blood-2005-02-0733. (Pubitemid 41510735)
155. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs. 2004;64:1997-2020 (pii:64181).
156. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis. 2003;37:728-32. doi:10.1086/377131. (Pubitemid 37100817)
157. Black KE, Baden LR. Fungal infections of the CNS: treatment strategies for the immunocompromised patient. CNS Drugs. 2007;21:293-318 (pii:2144).
158. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med. 1979;301:126-31. doi:10.1056/NEJM197907193010303. (Pubitemid 10225854)
159. Fan-Havard P, O'Donovan C, Smith SM, Oh J, Bamberger M, Eng RH. Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria. Clin Infect Dis. 1995;21:960-5.
160. Fisher JF, Sobel JD, Kauffman CA, Newman CA. Candida urinary tract infections - treatment. Clin Infect Dis. 2011;52:S457-66. doi:10.1093/cid/ cir112.
161. Khazim RM, Debnath UK, Fares Y. Candida albicans osteomyelitis of the spine: progressive clinical and radiological features and surgical management in three cases. Eur Spine J. 2006;15:1404-10. doi:10.1007/s00586-005-0038-z. (Pubitemid 44379286)
162. Schilling A, Seibold M, Mansmann V, Gleissner B. Successfully treated Candida krusei infection of the lumbar spine with combined caspofungin/ posaconazole therapy. Med Mycol. 2008;46:79-83. doi:10.1080/13693780701552996. (Pubitemid 351298245)
163. Kaldau NC, Brorson S, Jensen PE, Schultz C, Arpi M. Bilateral polymicrobial osteomyelitis with Candida tropicalis and Candida krusei: a case report and an updated literature review. Int J Infect Dis. 2012;16:e16-22. doi:10.1016/j.ijid.2011.10.001.
164. Slenker AK, Keith SW, Horn DL. Two hundred and eleven cases of Candida osteomyelitis: 17 case reports and a review of the literature. Diagn Microbiol Infect Dis. 2012;73:89-93. doi:10.1016/j.diagmicrobio.2012.02.004.
165. Micafungin lock therapy to clear fungemia while attempting to preserve central venous catheters. Trial code: NCT00809887. http://clinicaltrials.gov/.
166. McMullan R, Metwally L, Coyle PV, Hedderwick S, McCloskey B, O'Neill HJ, et al. A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin Infect Dis. 2008;46:890-6. doi:10.1086/528690. (Pubitemid 351417192)